Literature DB >> 26893763

MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.

Qianqian Shi1, Xianlin Xu1, Qing Liu1, Fengbao Luo1, Jian Shi1, Xiaozhou He1.   

Abstract

MicroRNAs (miRNAs) are involved in tumorigenesis. However, little is known about their role in renal cell carcinoma (RCC). In the present study, the function of the miRNA miR-877 in RCC was investigated, and its expression levels in blood and paired RCC tissues were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Bioinformatics analysis predicted eukaryotic elongation factor-2 kinase (eEF2K) to be the potential mRNA target of miR-877, which was verified by luciferase assay. The expression levels of eEF2K in RCC tissues were evaluated by western blot analysis and qPCR. The proliferation and migration abilities of RCC cells were measured by MTT and in vitro wound healing assays, respectively. The present results indicated that the expression levels of miR-877 were downregulated in blood and paired RCC tissues, whereas the expression levels of eEF2K were upregulated in RCC tissues. In addition, overexpression of miR-877 and knockdown of eEF2K significantly reduced the proliferation and migration abilities of RCC cells in vitro. Furthermore, miR-877 affected the eEF2K/eEF2 signaling pathway in these cells. In conclusion, the present study has demonstrated that miR-877 suppresses the proliferation and migration abilities of RCC cells by modulating the eEF2K/eEF2 signaling cascade. Therefore, miR-877 may be considered a potential biomarker for the diagnosis of RCC.

Entities:  

Keywords:  eukaryotic elongation factor-2 kinase; miR-877; renal cell carcinoma

Year:  2015        PMID: 26893763      PMCID: PMC4734253          DOI: 10.3892/ol.2015.4072

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  38 in total

1.  Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.

Authors:  L L Fu; T Xie; S Y Zhang; B Liu
Journal:  Apoptosis       Date:  2014-10       Impact factor: 4.677

2.  Optimizing patient adherence to targeted therapies in renal cell carcinoma.

Authors:  Patricia A Creel
Journal:  Clin J Oncol Nurs       Date:  2014-12       Impact factor: 1.027

3.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.

Authors:  Yunching Chen; Xiaodong Zhu; Xiaoju Zhang; Bin Liu; Leaf Huang
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

Review 4.  Autophagic pathways as new targets for cancer drug development.

Authors:  Bo Liu; Yan Cheng; Qian Liu; Jin-ku Bao; Jin-Ming Yang
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

5.  Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.

Authors:  Sandra Steffens; Frederik C Roos; Martin Janssen; Frank Becker; Julie Steinestel; Mahmoud Abbas; Konrad Steinestel; Gerd Wegener; Stefan Siemer; Joachim W Thüroff; Rainer Hofmann; Michael Stöckle; Mark Schrader; Arndt Hartmann; Kerstin Junker; Markus A Kuczyk; Andres J Schrader
Journal:  Virchows Arch       Date:  2014-09-02       Impact factor: 4.064

Review 6.  Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

Authors:  A W Tong; J Nemunaitis
Journal:  Cancer Gene Ther       Date:  2008-03-28       Impact factor: 5.987

Review 7.  Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.

Authors:  Hongcheng Zhu; Xi Yang; Jia Liu; Lu Zhou; Chi Zhang; Liping Xu; Qin Qin; Liangliang Zhan; Jing Lu; Hongyan Cheng; Xinchen Sun
Journal:  Cell Stress Chaperones       Date:  2014-09-24       Impact factor: 3.667

8.  Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines.

Authors:  Sonia Arora; Jin-Ming Yang; Terri Goss Kinzy; Ryutaro Utsumi; Tadashi Okamoto; Takashi Kitayama; Pedro A Ortiz; William N Hait
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

9.  Renal cell carcinoma: how to hit the targets?

Authors:  Oleg Banyra; Marjan Tarchynets; Alexander Shulyak
Journal:  Cent European J Urol       Date:  2014-01-27

10.  Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.

Authors:  Ibrahim Tekedereli; S Neslihan Alpay; Clint D J Tavares; Zehra E Cobanoglu; Tamer S Kaoud; Ibrahim Sahin; Anil K Sood; Gabriel Lopez-Berestein; Kevin N Dalby; Bulent Ozpolat
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

View more
  16 in total

1.  microRNA-877 contributes to decreased non-small cell lung cancer cell growth via the PI3K/AKT pathway by targeting tartrate resistant acid phosphatase 5 activity.

Authors:  Xue Bai; Changjun He; Bicheng Fu; Xianglong Kong; Jianlong Bu; Kaibin Zhu; Wei Zheng; Fucheng Zhou; Boxiong Ni
Journal:  Cell Cycle       Date:  2020-11-23       Impact factor: 4.534

2.  MicroRNA-877 is downregulated in cervical cancer and directly targets MACC1 to inhibit cell proliferation and invasion.

Authors:  Fanxu Meng; Jian Ou; Jinyu Liu; Xindi Li; Yanli Meng; Ling Yan; Ping Deng; Baosheng Sun
Journal:  Exp Ther Med       Date:  2019-09-09       Impact factor: 2.447

3.  MicroRNA-877 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting IGF-1R.

Authors:  Guohua Zhou; Jinglian Xie; Zikun Gao; Weishen Yao
Journal:  Exp Ther Med       Date:  2019-06-14       Impact factor: 2.751

Review 4.  Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer.

Authors: 
Journal:  Cancers (Basel)       Date:  2017-11-27       Impact factor: 6.639

5.  Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease.

Authors:  Rimpi Khurana; Glory Ranches; Simon Schafferer; Melanie Lukasser; Michael Rudnicki; Gert Mayer; Alexander Hüttenhofer
Journal:  RNA       Date:  2016-11-21       Impact factor: 4.942

6.  Serum level of co-expressed hub miRNAs as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.

Authors:  Qiang Su; Emily C Zhu; Yao-Long Qu; Di-Ya Wang; Wei-Wei Qu; Chen-Guang Zhang; Ting Wu; Zu-Hua Gao
Journal:  J Cancer       Date:  2018-10-11       Impact factor: 4.207

Review 7.  Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.

Authors:  Didem Karakas; Bulent Ozpolat
Journal:  J Mol Med (Berl)       Date:  2020-05-07       Impact factor: 4.599

8.  Eef2k is not required for fertility in male mice.

Authors:  Tianhao Feng; Shushu Zhou; Xiaodan Shi; Xin Zhang; Jintao Zhang; Shuqin Zhao; Xiaoyu Yang; Xuhui Meng; Mingxi Liu
Journal:  Transl Androl Urol       Date:  2021-05

9.  miR-877-3p targets Smad7 and is associated with myofibroblast differentiation and bleomycin-induced lung fibrosis.

Authors:  Cong Wang; Shen Gu; Honghui Cao; Zutong Li; Zou Xiang; Kebin Hu; Xiaodong Han
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

10.  MiR-877 suppresses gastric cancer progression by downregulating AQP3.

Authors:  Hongyu Zhu; Yulian Wu; Muxing Kang; Bo Zhang
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.